About the Company

SoftSeal®-STF is a hemostatic pad produced by Chitogen Inc. Chitogen is a medical device company dedicated to the development of next generation proprietary hemostatic products for the control of severe bleeding. Chitogen has a patented unique and versatile technology platform that will be developed into a number of differentiated products.


Hemostatic products are used in a wide range of applications and Chitogen is initially focusing on non-absorbable topical products for arterial puncture sites (primarily cardiac catheterizations) and trauma (military and emergency).



Founder and Chairman


Dr. Drake has held a number of senior positions including Founder and Chief Scientist for Medafor, Inc., Director of Microbiology for Surmodics, Inc., Vice President of Research of MediVators, Inc., Director of Research and Development for BallistiVet, Inc. Prior to these positions, he was a scientific researcher at the 3M Central Research and Life Science Sector Laboratories. He received his Ph.D. from the University of Minnesota specializing in Microbiology and Biochemistry.

Al Emola



Al Emola has had a long and distinguished career in the medical device industry.  He has served as President and CEO of StentTech, Vital Images and Flexmedics.  He has also worked for major medical device companies including St. Jude Medical, Bristol Myers/Squibb and American Hospital Supply.  Al has served as a director on several early stage medical device companies over his career including Medafor Inc.  He holds an MBA from Indiana University’s Kelley School of Business and a BS degree from the State University of New York.




Mr. Eayrs was the Founder and President of MedVest Capital, a FINRA-member firm that was sold to new owners in 2010. Previously he held positions as a Senior Research Analyst focused on medical technology companies at Dougherty & Company, LLC, and John G. Kinnard and Company, Inc. Mr. Eayrs is a Chartered Financial Analyst (CFA) and a member of the CFA Institute and the Twin Cities Society of Securities Analysts. Mr. Eayrs received an MA degree from Marquette University and a BA degree from the University of Minnesota.


VP of Operations and Regulatory Affairs


Dr. Ritter has previously been Operations Officer for development stage companies such as Ideal Implant. Alure Medical, and Halo Healthcare. His large company experience prepared him for directing and leading manufacturing, regulatory, quality systems, and new product development. He has been a VP for R&D at Mentor Corporation and Director of Technology Development at Johnson & Johnson. Dr. Ritter received his Ph.D. in Metallurgy and Biomaterials Science from the University of Pennsylvania, an MBA from the University of Connecticut and BS in Metallurgical Engineering from Polytechnic Institute of Brooklyn.




Dr. Levy is regarded for his leadership in healthcare management. As President and CEO, he established the first primary care center in Port St. Lucie and brought it exponential growth. Dr. Levy is Board Certified by and a diplomate of the American College of Healthcare Executives (ACHE), a Certified Physician Executive by the American College of Physician Executives, and a registered financial consultant. He earned his Doctor of Osteopathy from the University of Osteopathic Medicine and Health Sciences (UOMHS) after his Bachelor of Science in Chemistry from the University of Miami. Dr. Levy then received his MBA from Duke University with an additional certificate in Health Services Management. Dr. Levy served Chitogen as Interim CEO from December 2016 to January 2018.




Dr. Zhu is a retired Assistant Research Professor at Loma Linda University and is a co-inventor of the STF fiber. He has served as a consultant for Johnson & Johnson and Covidien. He has published numerous papers and has over 50 U.S. and international patents. Dr. Zhu is a graduate from Shanghai Medical College with the specialty of neurosurgery.




Mr. Albright currently leads a consulting practice at a global management consulting firm focusing on the Risk & Control environment within Operations and Technology and the convergence among Operational Risk, Compliance, and Internal Audit.  His experience covers strategy, operating model transformation and modernization, business transformation, crisis management, and the impact of digital innovation and intelligent process automation across the 3 Lines of Defense.  He possesses an MBA from Duke University and a BA in Economics from UCLA.  Additionally, he is a California CPA (inactive status).